Sulphonylurea derivatives are still efficacious in daily anti-diabetes clinical practice Case series report

Abstract

For a dozen or so years, we have been witnessing extraordinary advances in the treatment of type 2 diabetes. Researchers have been searching for drugs that are most effective in terms of metabolic control, reduced cardiovascular risk, reduced risk of hypoglycemic episodes, and improved pleiotropic effect. Novel anti-diabetic medications have also appeared on the market, demonstrating different mechanisms of action (e.g. incretin drugs, flosins). Additionally, the recently completed clinical trials on sulphonylurea derivatives have shed new light on that old class of drugs, demonstrating their safety and efficacy due to pancreatic and extra-pancreatic effects (gliclazide MR, glimepiride), and thus testifying to the fact that the well-known medications are still high on the list of anti-diabetic agents.